Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28649473 | 0.87 | MAN1B1 (0.55) | MAN1B1SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL28649474 | 0.87 | MAN1B1 (0.55) | MAN1B1SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL30597931 | 0.84 | SLC6A1 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL2895465 | 0.84 | CHRNA7 (0.36) | SLC6A2SLC6A4SLC6A3CHRNA7HPSE | |
| Trifluoroacetic Acid SCHEMBL4831016 | 0.84 | CCR5 (0.47) | SLC6A2SLC6A4SLC6A3CHRNA7CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL928724 | 0.84 | CCR5 (0.47) | SLC6A2SLC6A4SLC6A3CHRNA7CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL31309456 | 0.83 | HPSE (0.36) | MAN1B1SLC6A2SLC6A4SLC6A3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL28336835 | 0.82 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CHRNA7HPSE | |
| Trifluoroacetic Acid SCHEMBL30381174 | 0.82 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3CHRNA7HPSE | |
| Trifluoroacetic Acid SCHEMBL30165029 | 0.81 | SLC6A1 (0.47) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| CN-116969977-A | PAN-KRAS inhibitors | 北京华森英诺生物科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2906537-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10092572-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1515975-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6869962-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092572-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | MAN1B1 2236/4885SLC6A2 1410/4885SLC6A4 1570/4885 |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MAN1B1 3293/4885SLC6A2 4294/4885SLC6A4 3749/4885 |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAN1B1 2236/4885SLC6A2 1410/4885SLC6A4 1570/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MAN1B1 3293/4885SLC6A2 4294/4885SLC6A4 3749/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAN1B1 2236/4885SLC6A2 1410/4885SLC6A4 1570/4885 |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | TPD52L2, DPYD, CCND2 | MAN1B1 3841/4885SLC6A2 3892/4885SLC6A4 2298/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | MAN1B1 182/4885SLC6A2 4366/4885SLC6A4 4581/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | MAN1B1 2236/4885SLC6A2 1410/4885SLC6A4 1570/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | MAN1B1 2674/4885SLC6A2 3027/4885SLC6A4 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.